Novartis
India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec
By Jeanette Jakobsson | Posted on April 18, 2013
For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...
Recent contributors
Counsel, AU and NZ Patent Attorney
Senior Associate, China Patent Attorney
Associate, Attorney at Law
Counsel, European Patent Attorney
Partner, Attorney at Law, Business Area Manager
Partner, European Patent Attorney